Diffusion of Protease into Meat & Bone Meal for Solubility Improvement and Potential Inactivation of the BSE Prion by Coll, Brian A. et al.
Diffusion of Protease into Meat & Bone Meal for
Solubility Improvement and Potential Inactivation of the
BSE Prion
Brian A. Coll
1,2, Rafael A. Garcia
1*, William N. Marmer
1
1United States Department of Agriculture (USDA), Agricultural Research Service (ARS), Eastern Regional Research Center, Fats, Oils and Animal
Coproducts Research Unit, Wyndmoor, Pennsylvania, United States of America, 2Widener University, Department of Chemical Engineering, Chester,
Pennsylvania, United States of America
Background. Government-imposed feed bans have created a need for new applications for meat & bone meal (MBM). Many
potential new applications require MBM protein to be both soluble and free of infectious prion. Treatment with protease is
generally effective in reducing insoluble, thermally-denatured proteins to soluble peptides. It has been reported in the
literature that certain proteases, including Versazyme
TM, are able to degrade infectious prions in a system where the prions are
readily accessible to proteolytic attack. Prions distributed within MBM, however, may conceivably be protected from proteases.
Methodology/Principal Findings. The overall rate of proteolytic MBM digestion depends greatly on whether the protease
can penetrate deep within individual particles, or if the protease can only act near the surface of the particle. This research
examined the barriers to the diffusion of Versazyme
TM into particles of MBM. Confocal microscopy demonstrated differences in
the density distributions between the bone and the soft tissue particles of MBM. By tracking the diffusion of fluorescently
labeled Versazyme
TM through individual particles, it was found that bone particles show full Versazyme
TM penetration within
30 minutes, while penetration of soft tissue particles can take up to four hours, depending on the particle’s diameter. From the
variety of normal proteins comprising MBM, a specific protein was chosen to serve as a prion surrogate based on
characteristics including size, solubility, distribution and abundance. This surrogate was used to measure the effect of several
factors on Versazyme
TM diffusion. Conclusions/Significance. Results showed that surrogate distributed in bone particles was
more susceptible to degradation than that in soft tissue particles. Three factors controllable by unit operations in an industrial-
scale process were also tested. It was found that removing the lipid content and hydrating MBM prior to incubation both
significantly increased the rate of surrogate degradation. In a test of particle size, the smallest collected diameter range
demonstrated the largest degradation of the prion surrogate, suggesting milling would be beneficial.
Citation: Coll BA, Garcia RA, Marmer WN (2007) Diffusion of Protease into Meat & Bone Meal for Solubility Improvement and Potential Inactivation of
the BSE Prion. PLoS ONE 2(2): e245. doi:10.1371/journal.pone.0000245
INTRODUCTION
Meat & bone meal (MBM) is a product from the rendering of the
unmarketable animal tissue, primarily the bones and offal from
slaughtered livestock, the carcasses of deadstock, and meat
products that have exceeded their ‘sell-by’ dates [1]. Prior to the
United Kingdom’s outbreak of bovine spongiform encephalopathy
(BSE) in the 1980s, almost all MBM was utilized as a high-protein
ingredient in animal feed. Today, most countries do not allow
MBM containing any amount of ruminant tissue to be fed to
ruminant animals. In the United States, MBM with ruminant
tissue is used in feed for non-ruminant farm animals (especially
poultry and swine), companion animals, and aquaculture species,
which, with the exception of cats, have never been shown to
contract BSE under normal circumstances [2,3]. In the European
Union, MBM is banned from the feed of any animal that may
become human food [4]. In the EU, MBM is now primarily either
incinerated or used for its energy content in operations such as
cement plants [5,6], or used as an ingredient in pet food. The
Canadian government has recently passed a law that will ban
certain cattle tissues (known as ‘‘specified risk materials’’) from all
animal feeds, pet foods, and fertilizers [7].
While established outlets for MBM are threatened, the supply of
MBM is tied to meat production and thus relatively unresponsive
to changes in demand. The development of alternative outlets for
MBM is impeded by a couple of important barriers. Most
proposed applications for MBM, other than as a fuel, would take
advantage of the functional properties of MBM protein. These
functional properties are inaccessible unless the highly degraded
MBM protein is somehow made soluble, usually by hydrolysis [8–
11]. An application that successfully harnesses the protein’s
functional properties could be rejected due to concerns of BSE
prion contamination.
BSE prions are relatively resistant to hydrolysis, compared to
other proteins [12]. Prion-contaminated tissue can be rendered
noninfective by extended alkaline hydrolysis [13–15], but the
resulting material is extremely degraded and salty and retains little
value. Several research groups have identified enzymes capable of
digesting prion proteins [16–19], while other groups have
developed methods to increase the prion’s susceptibility to
protease digestion [20,21]. However, all past demonstrations have
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typically raw, homogenized neural tissue diluted with buffer is
treaded with the enzyme. These scenarios ignore the mass
transport barriers the MBM could impose, limiting access of
enzyme to prions distributed within MBM particles. Hypotheti-
cally, prions could be protected from enzymatic attack by the
matrix of rendered soft tissue or bone in which they would exist.
The enzyme may not be able to diffuse into fat-laden particles or
calcified bone tissue. Further, the overall rate of proteolytic MBM
digestion depends greatly on whether the protease can penetrate
deep within individual particles, or if the protease can only act
near the surface of the particle. Enzymatic digestion from the
surface only might be too slow for practical use.
The present research uses the commercial protease Versazy-
me
TM, and treats its ability to inactivate BSE prions as a given,
based on previous literature. The factors that affect the ability of
this enzyme to penetrate MBM particles are studied. The results
provide information critical to the design of a process to
simultaneously inactivate MBM prions and add functionality to
normal MBM protein.
MATERIALS AND METHODS
Meat & bone meal was obtained by the Fats and Proteins
Research Foundation (Alexandria, VA) from a member rendering
firm and provided to the researchers without revealing the identity
of the manufacturer, as described previously [1]. The anonymous
manufacturer provided detailed information on its raw material
and processing method; this information indicated that the MBM
was made entirely from cattle tissue, using a continuous, dry
rendering process.
Versazyme
TM was purchased from Bioresource International
(Morrisville, NC). Before use, Versazyme
TM was dissolved in
digestion buffer (see Table 1) and centrifuged to remove insoluble
impurities. All directly compared experiments used Versazyme
TM
from a single manufacturing lot.
The fluorescent label used was Alexa Fluor 633 (Molecular
Probes, Eugene, OR). All other chemicals used were of reagent or
molecular biology grade.
Fluorescent labeling
Before labeling, solutions of Versazyme
TM were fractionated by
size exclusion chromatography to remove protein impurities.
Using a Biologic DuoFlow Chromatography System (BIO-RAD,
Hercules, CA), a Superose 12 10/300 GL column (Tricorn,
Uppsala, Sweden) equilibrated with 0.05 M sodium phosphate
buffer, 0.15 M NaCl, pH 8.0 at 4uC was calibrated using
molecular weight standards. When processing solutions of
Versazyme
TM, eluent fractions predicted to contain Versazyme
TM
were collected and lyophilized.
The purified enzyme was treated with the fluorescent label
according the manufacturer’s directions. Briefly, a solution of
Alexa Fluor 633 in DMSO was added dropwise to a buffered
solution of Versazyme
TM. After one hour incubation, the protein-
label conjugates were separated from unreacted label using
a HiTrap Desalting column (Amersham Biosciences, Uppsala,
Sweden).
Confocal microscopy
The imaging system used consisted of an IRBE inverted light
microscope, connected to a TCS-SP1 Confocal Scanner Head
controlled by LCS-SP2 Leica Confocal Software (all components
from Leica Microsystems, Exton, PA). Images of the MBM
particles were produced using a 488 nm excitation laser while
viewing emission wavelengths from 500 nm to 565 nm. Images
showing the distribution of fluorescently-labeled Versazyme
TM,
were produced using a 633 nm excitation laser, while viewing
emission wavelengths from 650 nm to 710 nm.
A dilute solution with or without labeled enzyme was mixed with
MBM and this suspension was quickly transferred to a viewing dish.
Using the continuous scan function, the field of view, magnified to
20 times its true size, was moved until a suitable particle was
located, and then the magnification was increased by 4 or 8-fold
depending on the size of the particle. The z-plane focus was then
adjusted to show the plane passing approximately through the
center of the particle. In experiments with enzyme, images were
recorded at 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240, and
300 minutes. The process was conducted with three bone and
three soft tissue particles, which were selected at random.
Enzymatic digestion
Experiments involving the proteolytic digestion of MBM used
a solution of Versazyme
TM (0.2 mg/mL in protein solubilization
experiments; 0.1 mg/mL in target protein experiments) in digestion
buffer (see Table 1) at 50uC with constant shaking. MBM was
added to this solution at 1% (w/v). Control samples omitted
Versazyme
TM. At the end of a digestion period, reactions were
incubated at 90–100uC for 5 minutes to inactivate the enzyme.
Table 1. Reaction and analysis solutions
..................................................................................................................................................
Digestion buffer Mineral Extraction Solution Protein Extraction Solution SDS-PAGE loading buffer
pH 8.0 7.4 8.0 8.0
Tris (M) 0.01 - 0.01 0.01
EDTA (M) - 0.5 - 0.001
Urea (M) - - 7.0 -
Thiourea (M) - - 2.0 -
Sodium dodecyl sulfate (% w/v) - - 2.5 2.5
N-Lauroylsarcosine (% w/v) - - 1 -
2-Mercaptoethanol (% w/v) - - - 5.0
Dithiothreitol (M) - - 0.05 -
Protease inhibitor cocktail (% v/v) - - 0.02 -
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The amount of protein released into solution during an enzymatic
digestion was determined by a standard bicinconinic acid protein
concentration assay [22], using bovine serum albumin to construct
the standard curve.
Analysis of target protein hydrolysis
After a four-hour digestion, reaction suspensions were centrifuged
and the supernatants were discarded, in order to remove soluble
protein. The pellets were washed with deionized water and the
remaining solids were dried overnight in a vacuum oven at 40uC.
Each sample was then partially defatted by mixing with
chloroform for 5 minutes and then pouring through a Bu ¨chner
funnel fitted with Whatman #50 filter paper. To extract bone
mineral that might inhibit target protein solubility, samples were
then shaken with 10 mL of mineral extraction solution (see Table 1) at
4uC for 3 days. After this treatment the samples were centrifuged
and the supernatant was discarded.
After defatting and demineralizing, the target protein was
extracted from the solid material by mixing for four hours with
10 mL of a very aggressive protein-solubilizing solution, described
in Table 1 (protein extraction solution). This suspension was
centrifuged at 4uC and the supernatant was collected.
Extract concentration and exchange of the protein extraction
solution for SDS-PAGE loading buffer (Table 1) was achieved using
Amicon Diaflow Ultrafiltration Cells (Amicon, Lexington, MA)
fitted with 5,000 Da molecular weight cut off Molecular/Por
Cellulose Ester ultrafiltration membranes (Spectrum, Rancho
Dominguez, CA). These concentrated extracts were analyzed by
SDS-PAGE using the Phastsystem (Pharmacia, Uppsala, Sweden).
Phastgels with an 8–25% polyacrylamide gradient were used
according to the manufacturer’s protocol. The gels were stained
overnight with SYPRO Ruby Protein Gel stain (Sigma, St. Louis,
MO) according to the manufacturer’s directions.
To quantitate the target protein band on the gels, they were
scanned on a FLA-5000 Fluorescent Image Analyzer (Fujifilm,
Tokyo, Japan). The resulting image was analyzed using Multi
Gauge v2.02 (Fujifilm, Tokyo, Japan) quantitation software. The
concentration of target protein was determined by linear in-
terpolation between the concentration of a standard band of
known concentration and a clear background region on the gel.
Figure 1. Representative MBM particles autofluorescing. Particles in top row are soft tissue, particles in bottom row are bone. Arrows indicate
‘fissures’; white bar is 25 mm.
doi:10.1371/journal.pone.0000245.g001
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To prepare partially defatted MBM, 3 g MBM was extracted with
80 mL chloroform and then filtered through a Bu ¨chner funnel. To
prepare fractions of MBM that were primarily soft tissue or bone
particles, a heavy-fluid method adapted from Nash and Mathews
[23] was used. Approximately 4 g MBM and 80 mL of chloroform
were added to a graduated cylinder and stirred to break apart any
multi-particle clumps. This suspension was allowed to settle for
5 minutes, during which a large majority of the soft tissue particles
float to the surface and the bone particles sink to the bottom. The
liquid and suspended particles were then poured off and filtered,
leaving behind the bone particles. To prepare highly hydrated
MBM, 100 mg MBM was suspended in 9 mL digestion buffer and
incubated in a shaking water bath set at 25uC, 175 rpm for
20 hours. To prepare MBM fractions of different size ranges, 10 g
MBM was loaded on the top of a stack of half-height sieves (No. 7,
18, 25, 45, 60, 120 - US Alternative sieve designation system), and
Figure 2. Fluorescently labeled Versazyme
TM infusing into MBM particles. Top row (left to right) is a soft tissue particle 0, 20, 90 and 300 minutes after
exposure to the Versazyme
TM solution. Bottom row is a bone particle 0, 10, 30 and 60 minutes after exposure. White bar is 25 mm.
doi:10.1371/journal.pone.0000245.g002
Figure 3. Penetration of fluorescently labeled Versazyme
TM (represent-
ed by red color) into a bone particle, after 10 minutes incubation. Arrow
indicates a fissure in the particle. White bar is 25 mm.
doi:10.1371/journal.pone.0000245.g003
Figure 4. The increase in the solubility of MBM protein as proteolytic
digestion progresses. Open symbols represent control experiment with
Versazyme
TM omitted, closed symbols represent experiment with
Versazyme
TM (n=2, each data point; error bars represent 61 standard
deviation).
doi:10.1371/journal.pone.0000245.g004
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Tyler Company, Cleveland, OH). From this fractions labeled
‘small’ (passing through a sieve with 250 mm openings, but
retained on a sieve with 125 mm openings), ‘medium’ (710 mm,
355 mm), and ‘large’ (2800 mm, 1000 mm) were obtained.
RESULTS
Microscopic images of MBM particles were produced using
MBM’s inherent fluorescence, which is represented by green color
in Figure 1. Soft tissue and bone particles were easily differentiated
in these images; qualitatively, soft tissue particles were more
irregular in shape and more heterogeneous in density, compared
to bone particles. Many bone particles had fissures, extending
from the surface of the particle inward.
When bathed in a solution of fluorescently labeled Versazy-
me
TM, the enzyme was not obviously excluded from any portions
of either soft tissue or bone particles, given enough time (Figure 2).
The images illustrate the pattern of progressive enzyme infusion
observed in all particles studied. Labeled enzyme tended to reach
the centers of bone particles long before reaching the center of soft
tissue particles. It was apparent that Versazyme
TM infused much
more freely along fissures in bone particles (Figure 3). Under the
conditions tested, Versazyme
TM reached the center of particles
before they were visibly eroded due to proteolysis.
MBM protein resists dissolution under most conditions, in-
cluding the conditions used in the present work (Figure 4).
Versazyme
TM catalyzes the hydrolysis of MBM protein, reducing
insoluble MBM proteins to peptides small enough to dissolve into
the surrounding solution. Comparison of Figures 2 and 4 suggests
that this proteolysis is occurring throughout the particle rather
than just at the surface. The Versazyme
TM treated samples in
Figure 4 release approximately 20% of their total protein into
solution in 180 minutes; the images in Figure 2 show that
Versazyme
TM has penetrated deep into the MBM particles within
180 minutes.
Quantitative measurements on the relative importance of
various diffusion-inhibiting factors were achieved using a prion
surrogate. Rather than attempting to spike MBM with a prion
surrogate, a protein that occurs naturally in MBM was selected as
the surrogate. A 44 kDa protein (Figure 5) was chosen because it
met the following criteria: it is insoluble in the conditions used for
the enzymatic reaction, it is soluble and can be extracted under
special conditions so that it can be quantified by SDS-PAGE and
densitometery, it is present in both soft tissue and bone particles at
relatively high concentration, it can be hydrolyzed by Versazy-
me
TM, and it has a relatively high molecular weight. No attempt
was made to determine the identity of this surrogate protein.
Soft tissue and bone particles differ significantly in the amount
of diffusion resistance they present (Figure 6). The method used to
fractionate MBM into soft tissue and bone particles involves
floatation in chloroform, which has the side effect of partially
defatting the particles. To control for the effect of this defatting,
surrogate degradation in soft tissue and bone particles is compared
to surrogate degradation in MBM which was partially defatted in
the same manner. Considerably less surrogate was degraded in the
soft tissue particles, indicating that they presented greater obstacles
to diffusion.
Compared to untreated MBM, MBM that has been defatted,
rehydrated, or reduced in size presents less diffusion resistance
(Figure 7). Approximately twice as much surrogate was degraded
in particles that were either very small or well hydrated, compared
to untreated. Partial defatting had a smaller, but still significant
effect.
DISCUSSION
It is reasonable to question whether molecules as large as enzymes
can diffuse passively into dense MBM particles. Past studies with
plant tissue have often found that without assistance, enzymes
penetrate too slowly for practical purposes. Typically, application
of pressure or vacuum is required to accelerate infusion; these
treatments tend to force enzyme solution into air-filled pores in the
tissue. Culver et al. [24] found that without vacuum treatment,
infusion of a-amylase into apple cubes was too slow to be detected.
Pectinase fails to penetrate citrus peels even with pressure or
vacuum treatments, unless the outermost layer of the peel is first
mechanically scored [25]. Although there has been significant
Figure 5. SDS-PAGE. Lane 1 is crude Versazyme
TM, lane 2 is extract from
MBM incubated without Versazyme
TM, lane 3 is extract from MBM
incubated with Versazyme
TM. Arrow indicates band chosen as prion
surrogate.
doi:10.1371/journal.pone.0000245.g005
Figure 6. The effect of tissue type on the extent of prion surrogate
degradation (n=3, each data point; error bars represent 61 standard
deviation).
doi:10.1371/journal.pone.0000245.g006
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purposes such as the curing of ham [26,27], there are few
comparable studies using enzymes. One recent study [28]
successfully infused microbial transglutaminase into cattle hides,
but without respect to infusion rate.
In the present study, we observed that enzyme can penetrate
some portions of an individual MBM particle more rapidly than
others (Figures 2 and 3), resulting in a ‘diffusion front’ of varying
depth around the perimeter of a particle. Somewhat similar results
have been obtained with plant tissue. Varzakas et al. [29] observed
an irregular pattern of enzyme uptake by soybeans, which they
attributed to heterogeneity in cell type and orientation throughout
the bean. It is likely that similar factors affect the penetration of
Versazyme into MBM particles, but because MBM particles
originate in a variety of anatomical locations, cell type and
orientation probably varies widely from particle to particle.
Differences in tissue structure must account for the differences in
diffusion resistance between bone and soft tissue (Figure 6);
contrary to our expectations, rendered bone tissue does not
provide an enzyme-proof coating for bone protein.
Conclusion
The treatment of MBM with protease to increase solubility and
inactivate prions is technically possible. Neither tissue type
presents an insurmountable physical barrier to attack by Versazy-
me
TM, or presumably, other proteases of similar size. Soft tissue
particles’ greater resistance to enzyme infusion is concerning,
because these particles are more likely than bone particles to have
a high prion load.
Enzymatic treatments are often dismissed as being prohibitively
expensive for price-sensitive applications. This argument is
becoming progressively less valid as the enzyme-producing
industry matures, and enzyme prices drop. The enzyme used this
research is marketed primarily as an additive for poultry rations.
The practicality of a protease-MBM treatment process depends
largely on whether it can be designed to work rapidly with
a relatively small amount of enzyme. This research shows that
additional unit operations such as milling, solvent extraction, and
hydration improve the performance of the enzyme in such
a process by allowing the enzyme to rapidly penetrate and
hydrolyze throughout the particle, rather than just acting on the
particle’s surface. Further improvements might be achieved by
adopting the pressure or vacuum treatments that have been used
to force enzyme solution into plant tissue, but this depends largely
on the existence of gas-filled spaces within the particles.
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